Display options
Cite
Murat-Ringot A, Souquet PJ, Subtil F, et al. The Effect of Foot Reflexology on Chemotherapy-Induced Nausea and Vomiting in Patients With Digestive or Lung Cancer: Randomized Controlled Trial. JMIR Cancer. 2021;7(4):e25648doi: 10.2196/25648.
Murat-Ringot, A., Souquet, P. J., Subtil, F., Boutitie, F., Preau, M., & Piriou, V. (2021). The Effect of Foot Reflexology on Chemotherapy-Induced Nausea and Vomiting in Patients With Digestive or Lung Cancer: Randomized Controlled Trial. JMIR cancer, 7(4), e25648. https://doi.org/10.2196/25648
Murat-Ringot, Audrey, et al. "The Effect of Foot Reflexology on Chemotherapy-Induced Nausea and Vomiting in Patients With Digestive or Lung Cancer: Randomized Controlled Trial." JMIR cancer vol. 7,4 (2021): e25648. doi: https://doi.org/10.2196/25648
Murat-Ringot A, Souquet PJ, Subtil F, Boutitie F, Preau M, Piriou V. The Effect of Foot Reflexology on Chemotherapy-Induced Nausea and Vomiting in Patients With Digestive or Lung Cancer: Randomized Controlled Trial. JMIR Cancer. 2021 Nov 05;7(4):e25648. doi: 10.2196/25648. PMID: 34738909; PMCID: PMC8663669.
Copy Download .nbib Format: NLM
Share it on

JMIR Cancer. 2021 Nov 05;7(4):e25648. doi: 10.2196/25648.

The Effect of Foot Reflexology on Chemotherapy-Induced Nausea and Vomiting in Patients With Digestive or Lung Cancer: Randomized Controlled Trial.

JMIR cancer

Audrey Murat-Ringot, Pierre Jean Souquet, Fabien Subtil, Florent Boutitie, Marie Preau, Vincent Piriou

Affiliations

  1. Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
  2. INSERM U1290, Research on Healthcare Performance, Claude Bernard University I, Lyon, France.
  3. Groupe de Recherche en Psychologie Sociale EA 4163, Institut de Psychologie, Université Lyon 2, Bron, France.
  4. Pôle Santé Publique - Service de Biostatistiques, Hospices Civils de Lyon, Lyon, France.
  5. Biometrics and Evolutionary Biology UMR 5558, Claude Bernard University I, Centre national de la recherche scientifique, Villeurbanne, France.

PMID: 34738909 PMCID: PMC8663669 DOI: 10.2196/25648

Abstract

BACKGROUND: Cancer is a chronic disease with an incidence of 24.5 million and 9.6 million deaths worldwide in 2017. Lung and colorectal cancer are the most common cancers for both sexes and, according to national and international recommendations, platinum-based chemotherapy is the reference adjuvant treatment. This chemotherapy can be moderately to highly emetogenic. Despite antiemetic therapy, chemotherapy-induced nausea and vomiting (CINV) may persist. Moreover, cancer patients are increasingly interested in alternative and complementary medicines and have expressed the desire that nonpharmacological treatments be used in hospitals. Among alternative and complementary medicines, foot reflexology significantly decreases the severity of CINV in patients with breast cancer.

OBJECTIVE: The primary aim of this study was to assess the benefits of foot reflexology as a complement therapy to conventional treatments regarding the severity of acute CINV in patients with digestive or lung cancer. The secondary objectives assessed were the frequency and severity of delayed CINV, quality of life, anxiety, and self-esteem.

METHODS: This study was conducted between April 2018 and April 2020 in the Hospices Civils de Lyon, France. This was an open-label randomized controlled trial. Participants were randomized into two groups: the intervention group (ie, conventional care with foot reflexology; n=40) and the control group (ie, conventional care without foot reflexology; n=40). Foot reflexology sessions (30 minutes each) were performed on outpatients or inpatients. Eligible participants were patients with lung or digestive cancer with an indication for platinum-based chemotherapy.

RESULTS: The severity of acute nausea and vomiting was assessed with a visual analog scale during the second cycle of chemotherapy. A significant increase of at least 2 points was observed for the control group (7/34, 21%; P=.001). Across all cycles, the foot reflexology group showed a trend toward less frequent delayed nausea (P=.28), a significantly less frequent consumption of antiemetic drugs (P=.04), and no significant difference for vomiting (P=.99); there was a trend toward a perception of stronger severity for delayed nausea in the control group (P=.39). Regarding quality of life and anxiety, there was no significant difference between the intervention group and the control group (P=.32 and P=.53, respectively).

CONCLUSIONS: This study's results indicate that foot reflexology provides significantly better management of acute nausea severity and decreased consumption of antiemetic drugs in patients with lung or digestive cancer. In order to fulfill patients' desires to use nonpharmacological treatments and complementary and alternative medicines in hospitals, foot reflexology could be provided as a complementary intervention to conventional antiemetic drugs. Foot reflexology did not result in adverse effects. To assess the benefits of foot reflexology in routine practice, a larger study with several health care centers would be needed with a cluster randomized controlled trial.

TRIAL REGISTRATION: ClinicalTrials.gov NCT03508180; https://clinicaltrials.gov/ct2/show/NCT03508180.

INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.2196/17232.

©Audrey Murat-Ringot, Pierre Jean Souquet, Fabien Subtil, Florent Boutitie, Marie Preau, Vincent Piriou. Originally published in JMIR Cancer (https://cancer.jmir.org), 05.11.2021.

Keywords: cancer; chemotherapy; complementary and alternative medicine; foot reflexology; nausea and vomiting; randomized controlled trial

References

  1. Curr Oncol. 2018 Aug;25(4):e275-e281 - PubMed
  2. Ann Intern Med. 2017 Jul 4;167(1):40-47 - PubMed
  3. Maturitas. 2011 Feb;68(2):116-20 - PubMed
  4. Taehan Kanho Hakhoe Chi. 2005 Feb;35(1):177-85 - PubMed
  5. J Altern Complement Med. 2007 Jan-Feb;13(1):53-7 - PubMed
  6. Support Care Cancer. 2019 Jan;27(1):87-95 - PubMed
  7. Br J Nurs. 2016 Sep 8;25(16):S4-S11 - PubMed
  8. CA Cancer J Clin. 2018 Nov;68(6):394-424 - PubMed
  9. J Support Oncol. 2007 Feb;5(2 Suppl 1):5-12 - PubMed
  10. West J Nurs Res. 1989 Feb;11(1):128-32 - PubMed
  11. Support Care Cancer. 2007 May;15(5):497-503 - PubMed
  12. Support Care Cancer. 2010 Mar;18 Suppl 1:S1-10 - PubMed
  13. Recenti Prog Med. 2015 Dec;106(12):601-7 - PubMed
  14. CMAJ. 1996 Dec 15;155(12):1679-85 - PubMed
  15. Curr Oncol. 2015 Feb;22(1):13-9 - PubMed
  16. Ann Oncol. 2005 Apr;16(4):655-63 - PubMed
  17. Cancer Nurs. 2008 Mar-Apr;31(2):109-15 - PubMed
  18. Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21 - PubMed
  19. BMJ Qual Saf. 2019 Nov;28(11):875-886 - PubMed
  20. J Clin Oncol. 2006 Sep 20;24(27):4472-8 - PubMed
  21. Integr Cancer Ther. 2010 Dec;9(4):326-30 - PubMed
  22. Complement Ther Clin Pract. 2019 May;35:33-47 - PubMed
  23. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 - PubMed
  24. Bull Cancer. 2013 Sep;100(9):799-810 - PubMed
  25. Eur J Cancer. 2017 Nov;86:305-317 - PubMed
  26. Oncotarget. 2017 Feb 21;8(8):13440-13449 - PubMed
  27. Support Care Cancer. 2015 Jun;23(6):1795-806 - PubMed
  28. Oncol Nurs Forum. 2007 Jan;34(1):127-32 - PubMed
  29. Acta Psychiatr Scand. 1983 Jun;67(6):361-70 - PubMed
  30. Rev Pneumol Clin. 2017 Sep;73(4):172-179 - PubMed
  31. Ann Oncol. 2019 Feb 1;30(2):171-210 - PubMed
  32. Bull Cancer. 2016 May;103(5):469-77 - PubMed
  33. J Clin Oncol. 1997 Jan;15(1):116-23 - PubMed
  34. Percept Mot Skills. 2002 Feb;94(1):189-96 - PubMed
  35. Support Care Cancer. 2012 Jan;20(1):107-17 - PubMed
  36. Semin Oncol. 2011 Jun;38(3):358-61 - PubMed
  37. Bull Cancer. 2017 Sep;104(9):714-720 - PubMed
  38. Percept Mot Skills. 1979 Jun;48(3 Pt 1):840-2 - PubMed
  39. BMC Complement Altern Med. 2016 Sep 08;16:353 - PubMed
  40. Cancer. 2004 May 15;100(10):2261-8 - PubMed
  41. Lancet. 1985 Dec 21-28;2(8469-70):1425-6 - PubMed
  42. Asia Pac J Oncol Nurs. 2017 Jul-Sep;4(3):241-249 - PubMed
  43. Support Care Cancer. 2008 Feb;16(2):201-8 - PubMed
  44. Support Care Cancer. 2020 Aug;28(8):3921-3926 - PubMed
  45. JMIR Res Protoc. 2020 Jul 14;9(7):e17232 - PubMed
  46. Bull Cancer. 2019 May;106(5):497-509 - PubMed
  47. BMC Cancer. 2015 Feb 18;15:62 - PubMed
  48. Nurs Stand. 2000 Apr 19-25;14(31):33-8 - PubMed
  49. Oncologist. 2007;12 Suppl 1:4-10 - PubMed
  50. Eur J Cancer. 2010 Jan;46(2):312-22 - PubMed
  51. Eur J Oncol Nurs. 2005 Mar;9(1):21-32 - PubMed

Publication Types